Bayer
Bayer promotes Xarelto benefits
June 15, 2015Sales and Marketing Bayer, Eliquis, Xarelto, blood, law suits, rivaroxaban
Bayer HealthCare is releasing new evidence to suggest that the risk of taking its best-selling blood thinner Xarelto is outweighed …
Panasonic snaps up Bayer diabetes
June 12, 2015Medical Communications, Sales and Marketing Bayer, panasonic
Bayer is selling off its Diabetes Care business to Panasonic Healthcare Holdings, giving the Japanese giant access to blood glucose …
NICE issues guidance for two prostate cancer drugs
June 5, 2015Sales and Marketing Bayer, Ferring, NICE, firmagon, xofigo
NICE has published draft guidance for two prostate cancer drugs, recommending a Bayer medicine but rejecting one from Ferring Pharmaceuticals. …
Bayer and Gilead expand in manufacturing
June 2, 2015Manufacturing and Production, Sales and Marketing Bayer, Gilead, brett wells, manufacturing
Both Bayer and Gilead are investing heavily into their manufacturing operations with expansion plans being laid down in Indonesia and …
NICE signs-off Roche’s Gazyvaro for leukaemia
June 2, 2015Sales and Marketing Allergan, Bayer, CLL, Carole Longson, Eylea, Gazyvaro, NICE, Ozurdex, Roche, diabetic macular edema, leukaemia
NICE has given positive final guidance backing the use of Roche’s Gazyvaro for people with chronic lymphocytic leukaemia (CLL). Earlier …
Bayer wins Cancer Drugs Fund appeal
May 22, 2015Sales and Marketing Bayer, CDF, Cancer Drugs Fund, Eisai, NHS, lilly
Bayer is the only company to win its appeal to NHS England in the latest round of Cancer Drugs Fund …
Bayer buys blood-thinning drug from Isis
May 5, 2015Research and Development, Sales and Marketing Bayer, Eliquis, ISIS-FXI, Isis, Xarelto, blooding thinning
German drug giant Bayer is sealing a $155 million deal with Isis Pharmaceuticals to gain access to its anti-clotting treatment …
Profits fall at Bayer but new drugs see growth
May 1, 2015Sales and Marketing Bayer, Eliquis, Eylea, Renegeron, Xarelto, apixaban
Bayer’s pharmaceutical revenues have continued their upward trajectory in the first quarter of 2015 thanks to new products, although this …
Boehringer Ingelheim and Bayer ‘taking the lead’ in social media
April 22, 2015Medical Communications, Sales and Marketing Bayer, Boehringer Ingelheim, J&J and Merck, Novartis, Ogilvy Healthworld
Pharma may be finally embracing social media as a vehicle for engaging with doctors and patients, after posting more than …
Drug development showcasing at AACR conference
April 13, 2015Research and Development, Sales and Marketing American Association of Cancer Research, AstraZeneca, Bayer, Genentech, Novartis, aacr
This month’s American Association of Cancer Research conference is set to showcase the latest studies in oncology. Roche’s biotech subsidiary …
Bayer and Regeneron eye drug gains another indication
March 26, 2015Sales and Marketing Bayer, Eylea, FDA, Japan, Lucentis, MRI, Regeneron, aflibercept
Bayer and Regeneron’s Eylea has added to a growing list of indications with its new approval to treat a type …
NICE decisions made on Bayer, Celgene and Boehringer drugs
March 26, 2015Sales and Marketing Bayer, Boehringer, Celgene, NHS, Xarelto, imnovid, jardiance
In final guidance NICE has recommended Bayer’s Xarelto and Boehringer’s Jardiance for NHS funding, but not Celgene’s Imnovid. Bayer’s Xarelto …
Merck and Eisai partner on cancer therapy trial
March 6, 2015Research and Development, Sales and Marketing Bayer, Cancer, FDA, Halaven, Lenvima, Merck, Stivarga, keytruda, oncology, pd1
Merck and Eisai are teaming up for collaborative trials to test the effects of using combinations of each company’s oncology …
New EU indication for Bayer and Regeneron eye drug
February 27, 2015Sales and Marketing Bayer, European Commission, Eylea, aflibercept
Bayer and Regeneron’s Eylea is now indicated for every type of the eye disease retinal vein occlusion (RVO) thanks to …
Ousted Sanofi boss finds role at PureTech
February 27, 2015Sales and Marketing Bayer, Sanofi, Viehbacher, baumann, brandicourt, pott, puretech
US science and technology R&D company PureTech has appointed the former Sanofi chief executive Christopher Viehbacher to its board. Viehbacher …
Latest content
